Search Results

Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in a Phase III trial.

Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to develop and commercialize mosliciguat, a potential first-in-class inhaled soluble guanylate cyclase activator.

The Switzerland layoffs are the latest in Bayer’s 2024 workforce reductions, which already include 1,500 people and nearly half of the executive leadership team.

Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd., announced that it is extending its joint validation trials for its biofungicides conducted by Bayer AG, a global leader in the agriculture industry, after successful first-year laboratory and greenhouse testing.

With the late-stage win, Bayer announced Monday that it plans to talk to regulators about seeking approval in an indication that is central to its $3 billion-plus peak sales forecast.

Bayer’s surprising growth in the second quarter was driven in large part by two pharma products: the prostate cancer drug Nubeqa and the chronic kidney disease treatment Kerendia.

Bayer AG (BAYRY), a leading global pharmaceutical and biotechnology company, and TetraScience, the Scientific Data and AI Cloud company, today announced an agreement aimed at maximizing the value of scientific data and driving innovation.

As experts from around the globe gather at the annual Society for Informatics in Medicine conference, Bayer and Rad AI are announcing a collaboration to bring Rad AI’s cutting edge AI radiology operational solutions to Calantic ™ Digital Solution customers.

Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.

Mass layoffs represent a step for Bayer toward reducing managerial layers, while clinical results released in the last week could influence the parallel races between Novo Nordisk and Eli Lilly in the GLP-1 and insulin spaces.